The table below shows BeOne Medicines AG's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
$201.34M
$44.08M
-$308.57M
-$563.78M
-$236.56M
$125.09M
Capital expenditure
$40.79M
$56.41M
$156.58M
$125.58M
$45.13M
$42.39M
Investing cash flow
-$45.51M
-$121.94M
-$209.83M
$241.06M
$210.39M
$291.95M
Dividends paid
-
-
-
-
ONC operating cash flow (10-K history)
BeOne Medicines AG reported operating cash flow of $1.13B for fiscal year 2025. That is up 901.8% from -$140.63M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$89.51M (FY 2016) to $1.13B. Figures come from the company's audited annual reports as filed with the SEC.